mayo clinic glp-1 program Weight-Loss Medications Primary Care in Rochester and

All of the dynamics around GLP-1s, compounding shortage workarounds, and potential for DTC telehealth fallout I described last August seem to be playing out in 2025

GLP-1 medications like semaglutide are not recommended for individuals with a history of: Medullary thyroid carcinoma (or a family history of it) Multiple endocrine neoplasia syndrome type 2 (MEN 2) Pancreatitis or gallbladder disease Severe gastrointestinal disorders FuturHealth clinicians screen all patients for these risk factors during the onboarding process

95% CI: 0.581.14)

Before you get tempted to purchase the next miracle capsule or appetite suppressant, heres some information on what weight loss pills can and cant do, and what Ontario health authorities and doctors recommend

When combining insights from Morningstar Sustainalytics ESG Risk Ratings and Morningstar Equity Research (depicted in Exhibit 1), we find that Pfizer PFE and Roche RHHBY stand out as potential top choices among potential future market entrants, whereas Novo Nordisk NVO appears undervalued among current players

However, current systematic conclusions about weight regain mostly came from the studies of bariatric surgery or behavioral interventions